| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5988300 | The Journal of Thoracic and Cardiovascular Surgery | 2016 | 27 Pages |
Abstract
Edaravone can protect the BMSCs against hypoxia and activate their potential to activate CSCs via the Akt pathway. The combined treatment can promote angiogenesis, resident CSC-mediated myocardial regeneration, and cardiac function after AMI, providing a new strategy for cell therapy.
Keywords
RFPcTNTHGFConnexin43PCICX43bFGFBMSCCSCIGF-15-bromo-2-deoxyuridineCXCR4ROSMyocardial infarctionEdaravoneRegenerationBrdUcardiac troponin Tcluster of differentiationcardiac stem cellBone marrow mesenchymal stem cellHepatocyte growth factorVentricular functionVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)basic fibroblast growth factorinsulin-like growth factor 1percutaneous coronary interventionred fluorescent proteinStem cell transplantationReactive oxygen speciesCXC chemokine receptor 4
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Guang-Wei MD, Tian-Xiang MD, Xue-Jun MD, Chunyue MD, Xun MD, Xiao-Bing MD, Jesse MD, PhD,